Search company, investor...
Galera Therapeutics company logo

Galera Therapeutics



Total Raised


Date of IPO


Market Cap


About Galera Therapeutics

Galera Therapeutics (NASDAQ: GRTX) develops drugs targeting oxygen metabolic pathways. The Company's lead compounds are highly selective small molecule dismutase mimetics that closely mimic the activity of the human superoxide dismutase enzymes. While the biology of the superoxide dismutase family suggests a broad range of potential applications, Galera is focusing its development on the prevention of radiation-induced toxicity, including mucositis, and the treatment of cancer.

Headquarters Location

2 West Liberty Boulevard Suite 110

Malvern, Pennsylvania, 19355,

United States


Missing: Galera Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Galera Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Galera Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Galera Therapeutics is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Galera Therapeutics Patents

Galera Therapeutics has filed 8 patents.

The 3 most popular patent topics include:

  • Chlorides
  • Chloro complexes
  • Coordination compounds
patents chart

Application Date

Grant Date


Related Topics




Nitrogen heterocycles, Inflammations, Chelating agents, Lactams, Immunology


Application Date


Grant Date



Related Topics

Nitrogen heterocycles, Inflammations, Chelating agents, Lactams, Immunology



Latest Galera Therapeutics News

Piper Sandler Initiates Coverage of Galera Therapeutics With Overweight Recommendation

Feb 22, 2023

On February 21, 2023, Piper Sandler initiated coverage of Galera Therapeutics with a Overweight recommendation. Analyst Price Forecast Suggests 493.02% Upside As of February 19, 2023, the average one-year price target for Galera Therapeutics is $10.20. The forecasts range from a low of $2.02 to a high of $18.90. The average price target represents an increase of 493.02% from its latest reported closing price of $1.72. The projected annual revenue for Galera Therapeutics is $8MM. The projected annual EPS is -$1.31. What are large shareholders doing? Sofinnova Investments holds 3,084K shares representing 7.20% ownership of the company. No change in the last quarter. Novo Holdings A holds 2,459K shares representing 5.74% ownership of the company. No change in the last quarter. Blackstone Group holds 1,679K shares representing 3.92% ownership of the company. No change in the last quarter. Sectoral Asset Management holds 1,667K shares representing 3.89% ownership of the company. Tekla Capital Management holds 898K shares representing 2.10% ownership of the company. No change in the last quarter. What is the Fund Sentiment? There are 50 funds or institutions reporting positions in Galera Therapeutics. This is a decrease of 7 owner(s) or 12.28% in the last quarter. Average portfolio weight of all funds dedicated to GRTX is 0.03%, an increase of 4.72%. Total shares owned by institutions increased in the last three months by 14.40% to 13,234K shares. The put/call ratio of GRTX is 0.01, indicating a bullish outlook. Galera Therapeutics Background Information (This description is provided by the company.) Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera’s lead product candidate is avasopasem manganese (GC4419, also referred to as avasopasem), a highly selective small molecule superoxide dismutase (SOD) mimetic initially being developed for the reduction of radiation-induced severe oral mucositis (SOM). Avasopasem is being studied in the Phase 3 ROMAN trial to assess its ability to reduce the incidence and severity of SOM induced by radiotherapy in patients with locally advanced head and neck cancer (HNC), its lead indication. It is also being studied in the EUSOM Phase 2a multi-center trial in Europe assessing the safety of avasopasem in patients with HNC undergoing standard-of-care radiotherapy, the AESOP Phase 2a trial to assess its ability to reduce the incidence of esophagitis induced by radiotherapy in patients with lung cancer, and a Phase 2 trial in hospitalized patients who are critically ill with COVID-19. A pilot Phase 1/2 trial of avasopasem in combination with stereotactic body radiation therapy (SBRT) in patients with locally advanced pancreatic cancer (LAPC) has completed enrollment and reported interim results, with follow-up ongoing. The FDA granted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of SOM induced by radiotherapy. Galera’s second dismutase mimetic product candidate, GC4711, is being developed specifically to augment the anti-cancer efficacy of SBRT, and is currently being studied in the GRECO-1 Phase 1/2 trial in combination with SBRT in patients with non-small cell lung cancer. Galera is headquartered in Malvern, PA. This article originally appeared on Fintel Sponsored: Find a Qualified Financial Advisor Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now .

Galera Therapeutics Frequently Asked Questions (FAQ)

  • Where is Galera Therapeutics's headquarters?

    Galera Therapeutics's headquarters is located at 2 West Liberty Boulevard, Malvern.

  • What is Galera Therapeutics's latest funding round?

    Galera Therapeutics's latest funding round is IPO.

  • How much did Galera Therapeutics raise?

    Galera Therapeutics raised a total of $142.94M.

  • Who are the investors of Galera Therapeutics?

    Investors of Galera Therapeutics include Clarus, New Enterprise Associates, Novartis Venture Funds, Correlation Ventures, Sofinnova Ventures and 15 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.